Technology Transfer Office
Search
Actualité - Innovation

Cap'CARNOT 2021

Institut Curie
09/13/2021
Share
On September 28th, Carnot Curie Cancer will be present at Cap'CARNOT 2021, the annual meeting of Carnot with the actors of innovation. This year, Cap'CARNOT will celebrate the 15 years of R&D actions of Carnot at the service of business innovation. On this occasion, two innovations born from our Institute and from partnerships with industrials will be highlighted: AsiDNA and Cinesteam.
Cap'Carnot 2021
Cap'CARNOT 2021

Date: September, 28th

Location: NEWCAP

Organizer: Le réseau des Carnot

On September 28th, Carnot Curie Cancer will be present at Cap'CARNOT 2021, the annual meeting of Carnot with the actors of innovation. This year, Cap'CARNOT will celebrate the 15 years of R&D actions of Carnot at the service of business innovation. On this occasion, two innovations born from our Institute and from partnerships with industrials will be highlighted: AsiDNA and Cinesteam.

 

Cinesteam®: the anti-odour dressing

Cinesteam® is an anti-odour absorbent dressing that has been developed to improve the comfort of patients, their families and caregivers. Indeed, of all the symptoms associated with wounds, odor is cited by patients and caregivers as the most distressing, leading to social isolation and disgust. This innovative medical device provides effective management of malodorous wounds by eliminating malodors through a dual mechanism. The non-adhesive dressing consists of a pouch containing cinnamon powder and an absorbent layer to absorb excess exudate from the primary dressing. The cinnamon retains volatile malodorous compounds from the wounds while masking residual malodors by emitting a pleasant spicy odor.

Cinesteam® is the result of research conducted by Isabelle Fromantin, nurse and researcher, head of Institut Curie's Wounds and Healing Unit, in partnership with ESPCI Paris, Chimie-ParisTech and Cemag Care, which led to the filing of a patent and the development of this dressing.

AsiDNA™: the product that targets the DNA damage response

The AsiDNA™ technology originates from the work of DNA Therapeutics, a spin-off from Institut Curie, CNRS and the Muséum National d'Histoire Naturelle, which was founded in 2006 and acquired by the biotechnology company Onxeo in 2016. AsiDNA™ is a double-stranded DNA fragment that acts as a decoy, mimicking a DNA double-strand break in the tumor cell. AsiDNA™ sends a false damage signal that mobilizes DNA break detection and repair enzymes and prevents the repair of real DNA damage. Cancer cells continue to divide despite these breaks, ultimately inducing their cell death. Healthy cells, on the other hand, do not divide any more until they can repair their DNA once the product is released from the body.